Entity

Time filter

Source Type

Baltimore Highlands, MD, United States

Kim D.-H.,Johns Hopkins University | Cho S.,Johns Hopkins University | Wirtz D.,Johns Hopkins University | Wirtz D.,Sydney Kimmel Comprehensive Cancer Center
Journal of Cell Science | Year: 2014

Although eukaryotic cells are known to alternate between 'advancing' episodes of fast and persistent movement and 'hesitation' episodes of low speed and low persistence, the molecular mechanism that controls the dynamic changes in morphology, speed and persistence of eukaryotic migratory cells remains unclear. Here, we show that the movement of the interphase nucleus during random cell migration switches intermittently between two distinct modes-rotation and translocation-that follow with high fidelity the sequential rounded and elongated morphologies of the nucleus and cell body, respectively. Nuclear rotation and translocation mediate the stopand-go motion of the cell through the dynamic formation and dissolution, respectively, of the contractile perinuclear actin cap, which is dynamically coupled to the nuclear lamina and the nuclear envelope through LINC complexes. A persistent cell movement and nuclear translocation driven by the actin cap are halted following the disruption of the actin cap, which in turn allows the cell to repolarize for its next persistent move owing to nuclear rotation mediated by cytoplasmic dynein light intermediate chain 2. © 2014. Published by The Company of Biologists Ltd. Source


Kim D.-H.,Johns Hopkins University | Chambliss A.B.,Johns Hopkins University | Wirtz D.,Johns Hopkins University | Wirtz D.,Sydney Kimmel Comprehensive Cancer Center
Soft Matter | Year: 2013

The perinuclear actin cap (or actin cap) is a recently characterized cytoskeletal organelle composed of thick, parallel, and highly contractile acto-myosin filaments that are specifically anchored to the apical surface of the interphase nucleus. The actin cap is present in a wide range of adherent eukaryotic cells, but is disrupted in several human diseases, including laminopathies and cancer. Through its large terminating focal adhesions and anchorage to the nuclear lamina and nuclear envelope through LINC complexes, the perinuclear actin cap plays a critical role both in mechanosensation and mechanotransduction, the ability of cells to sense changes in matrix compliance and to respond to mechanical forces, respectively. © 2013 The Royal Society of Chemistry. Source


Messing B.P.,Jr Head And Neck Center | Kim M.,Jr Head And Neck Center | Hirata R.,Jr Head And Neck Center | Gebhart S.,Sydney Kimmel Comprehensive Cancer Center | And 4 more authors.
Laryngoscope | Year: 2015

Objectives/Hypothesis The objective of this study was to evaluate the effectiveness of nystatin and Biotène® mouthwash Oral Rinse for controlling Candida in total laryngectomy (TL) patients with a tracheosophageal voice prosthesis (TEP) because Biotène® mouthwash Oral Rinse is a less costly alternative to nystatin and requires less adherence time. Study Design Randomized, unblinded, crossover trial. Methods Twenty-one TL patients were randomized to receive nystatin followed by Biotène® mouthwash Oral Rinse, or the reverse order, after a basic oral-care phase (i.e., brushing teeth, cleaning dentures). A Provox® 2, 22.5 French TEP, which is an indwelling silicone voice prosthesis, was placed at the beginning of each phase. Patients were provided with oral care instructions at randomization and medication-specific instructions with each treatment's initiation. TEPs were processed and evaluated for Candida growth as colony-forming units (CFUs). Wilcoxon signed-rank tests were used for comparisons between treatments. Results Fifteen patients were available for comparisons of Candida counts (6 received nystatin; 9 received Biotène® mouthwash first). Overall, the median log10 (CFUs) remained high regardless of treatment (no medication: 8.9; nystatin: 8.7; Biotène® mouthwash: 8.4). However, the median counts for both nystatin and Biotène® mouthwash Oral Rinse were lower than those for no medication (difference [Δ]:-0.9 and -0.3, respectively), although only nystatin was significantly lower (P=0.02). There was no significant difference between the two treatments (P=0.22). Overall, median medication-adherence was high (97%), and Biotène® mouthwash adherence was significantly higher than that of nystatin (Δ: 7.6%; P=0.03). Conclusion Nystatin and Biotène® mouthwash Oral Rinse had similar CFU levels, with nystatin showing a significant improvement over usual oral care. Biotène® mouthwash is a less costly alternative to nystatin, with a less complex treatment protocol that might make it preferable to patients and clinicians. © 2014 The American Laryngological, Rhinological and Otological Society, Inc. Source


Aifuwa I.,Johns Hopkins University | Giri A.,Johns Hopkins University | Longe N.,Johns Hopkins University | Lee S.H.,Johns Hopkins University | And 3 more authors.
Oncotarget | Year: 2015

Cells induced into senescence exhibit a marked increase in the secretion of pro-inflammatory cytokines termed senescence-associated secretory phenotype (SASP). Here we report that SASP from senescent stromal fibroblasts promote spontaneous morphological changes accompanied by an aggressive migratory behavior in originally non-motile human breast cancer cells. This phenotypic switch is coordinated, in space and time, by a dramatic reorganization of the actin and microtubule filament networks, a discrete polarization of EB1 comets, and an unconventional front-to-back inversion of nucleus-MTOC polarity. SASP-induced morphological/migratory changes are critically dependent on microtubule integrity and dynamics, and are coordinated by the inhibition of RhoA and cell contractility. RhoA/ROCK inhibition reduces focal adhesions and traction forces, while promoting a novel gliding mode of migration. Source


Li D.,Sloan Kettering Cancer Center | Pant S.,Peggy and Charles Stephenson Oklahoma Cancer Center | Ryan D.P.,Massachussetts General Hospital | Laheru D.,Sydney Kimmel Comprehensive Cancer Center | And 10 more authors.
Pancreatology | Year: 2014

Background Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into cells. CO-1.01 (gemcitabine-5′-elaidate) is a novel cytotoxic agent consisting of a fatty acid derivative of gemcitabine, which is transported intracellularly independent of hENT1. CO-1.01 was postulated to have efficacy as a second-line treatment in gemcitabine-refractory pancreatic adenocarcinoma in patients with negative tumor hENT1 expression.Methods Eligibility criteria included patients with either a newly procured or archival biopsy tumor confirming the absence of hENT1 and either gemcitabine-refractory metastatic pancreas adenocarcinoma or with progression of disease following resection during or within 3 months of adjuvant gemcitabine therapy. Patients were treated with intravenous infusion of CO-1.01 dosed at 1250 mg/m2 on Days 1, 8, and 15 of a 4-week cycle. The primary end point was disease control rate (DCR).Results Nineteen patients were enrolled of which 18 patients were evaluable for efficacy assessment. Thirteen patients (68%) had liver metastases, 6 (32%) had lymph node metastases, and 10 (53%) had lung metastases. Two of 18 patients (11%) achieved disease control. The median survival time was 4.3 (95% CI 2.1-8.1) months. All patients experienced at least one treatment-related adverse event with the majority of events being mild or moderate.Conclusion This study did not meet its primary endpoint and no efficacy signal was identified for CO-1.01 in treating progressive metastatic pancreas adenocarcinoma. © 2014, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. Source

Discover hidden collaborations